DSP-3077 Retinal Sheet Cohort 2

Small molecule

DSP-3077 Retinal Sheet Cohort 2 is one of 31 small molecule programs targeting Retinitis Pigmentosa. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Retinitis PigmentosaActive, not recruiting

Retinitis PigmentosaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

73 competitors in Retinitis Pigmentosa

#DrugCompanyPhaseTrials

Cysteine Hydrochloride

Novartis

Phase 3

1 2

Aquasol a

BBandim Health Project

Phase 3

2 3

Minocin

TTriax

Phase 3

2 4

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 5

Depakote

AbbVie

Phase 2

2 6

Eylea

Regeneron

Phase 2

1 7

Alphagan

AbbVie

Phase 2

1 8

Lutein

NNational Eye Institute (NEI)

Phase 3

2 9

Levodopa-Carbidopa

AbbVie

Phase 2

1 10

N-Acetylcysteine Amide

NNacuity Pharmaceuticals, Inc.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 1/2Recruiting

Retinitis Pigmentosa

NCT06891885

Clinical

Trials by Indication[1]

Retinitis Pigmentosa1 trial

A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Recruiting· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT06891885·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DSP-3077 Retinal Sheet Cohort 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DSP-3077 Retinal Sheet Cohort 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DSP-3077 Retinal Sheet Cohort 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Sumitomo Pharma America, Inc.

DSP-3077 Retinal Sheet Cohort 2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Retinitis Pigmentosa1 trial

References

Drug Info

Quick Facts

Related News